This is reflected by the latest clinical practice guidelines of the European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) recommending genotyping of tumor tissue (primary or metastatic) for the presence of KRAS exon 2 mutations as well as non-exon 2 mutations and NRAS mutations [9, 16]. This evidence concerns the gene KRAS and neoplasm.